VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients...

VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion Brisbane, Australia 26th June 2018: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to confirm that screening in the Company’s Phase 2 clinical trial VF00102 will close at the end of June, marking the final step before full recruitment. “We’ve continued to make excellent progress this month, to the point where we have informed all our sites that the deadline for new patients to be screened for the trial is the 29th of June. So far this month we’ve randomised 10 patients, bringing the total recruited to 145; and we have a strong pipeline of patients coming through screening,” said Dr Ros Wilson, CEO of Factor Therapeutics. With screening closed, the last patients to enter the trial will be assessed for randomisation over the following two weeks. At the end of this period, with between 150 and 155 patients expected to be enrolled, recruitment will be complete and top-line efficacy results will be delivered just over three months later. Dr Wilson added, “The low number of withdrawals has persisted and is a very encouraging sign of patients being motivated to stay on study. This has been a key factor in the final recruitment goal, combined with the expert statistical review we obtained when the trial analysis plan was finalised in May. We’re excited that recruitment will soon be complete but, more importantly, that we will shortly have results. In the meantime, our efforts are firmly focused on continuing to drive partnering discussions and preparing for interactions with regulatory authorities following readout.” -ENDS- Contact for Further Information: Dr. Rosalind Wilson Chief Executive Officer Factor Therapeutics Limited [email protected] About Factor Therapeutics Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit https://factor-therapeutics.com